Zacks: Brokerages Anticipate Depomed, Inc. (ASRT) to Post $0.20 EPS

Analysts predict that Depomed, Inc. (NYSE:ASRT) will announce $0.20 earnings per share (EPS) for the current fiscal quarter, according to Zacks. Three analysts have made estimates for Depomed’s earnings. The lowest EPS estimate is $0.12 and the highest is $0.31. Depomed posted earnings of $0.14 per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 42.9%. The firm is expected to report its next earnings results after the market closes on Thursday, November 8th.

On average, analysts expect that Depomed will report full-year earnings of $0.84 per share for the current year, with EPS estimates ranging from $0.66 to $0.96. For the next fiscal year, analysts expect that the business will report earnings of $0.72 per share, with EPS estimates ranging from $0.64 to $0.80. Zacks’ earnings per share calculations are an average based on a survey of sell-side research firms that cover Depomed.

Depomed (NYSE:ASRT) last released its earnings results on Wednesday, August 8th. The company reported ($0.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.03). The business had revenue of $63.27 million during the quarter, compared to analyst estimates of $63.60 million.

A number of analysts have weighed in on the company. Zacks Investment Research lowered Depomed from a “buy” rating to a “hold” rating in a research note on Tuesday. Roth Capital reiterated a “buy” rating on shares of Depomed in a research note on Tuesday, August 21st. Finally, Janney Montgomery Scott lowered Depomed from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 29th.

ASRT stock opened at $5.21 on Friday. Depomed has a twelve month low of $4.31 and a twelve month high of $9.48.

Depomed Company Profile

Assertio Therapeutics, Inc, a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; and Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults.

Featured Article: The Discount Rate – What You Need to Know

Get a free copy of the Zacks research report on Depomed (ASRT)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Depomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Depomed and related companies with's FREE daily email newsletter.

Leave a Reply